AXS-02 (oral zoledronate) + Placebo
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Complex Regional Pain Syndrome
Conditions
Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy
Trial Timeline
Jul 1, 2015 → Jan 1, 2019
NCT ID
NCT02504008About AXS-02 (oral zoledronate) + Placebo
AXS-02 (oral zoledronate) + Placebo is a phase 3 stage product being developed by Axsome Therapeutics for Complex Regional Pain Syndrome. The current trial status is unknown. This product is registered under clinical trial identifier NCT02504008. Target conditions include Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02504008 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Complex Regional Pain Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zonisamide | Eisai | Phase 3 | 77 |
| Eslicarbazepine acetate + Eslicarbazepine acetate | Sumitomo Pharma | Phase 3 | 77 |
| Everolimus (RAD001) + Everolimus Placebo | Novartis | Phase 3 | 77 |
| Zoledronic acid + Placebo | Novartis | Phase 2 | 52 |
| RAD001 + Placebo | Novartis | Phase 2 | 52 |
| RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase) | Novartis | Phase 3 | 77 |
| everolimus | Novartis | Phase 3 | 77 |
| ranolazine | Gilead Sciences | Phase 2 | 51 |
| clarithromycin, rifabutin | Pfizer | Approved | 84 |
| Pregabalin + Pregabalin | Pfizer | Approved | 84 |
| Pregabalin | Pfizer | Pre-clinical | 22 |
| Azithromycin | Pfizer | Approved | 84 |
| Azithromycin + Rifabutin/rifampin | Pfizer | Approved | 84 |
| Stavudine | Bristol Myers Squibb | Phase 3 | 76 |
| Zidovudine + Didanosine | Bristol Myers Squibb | Phase 2 | 51 |
| Haemocomplettan® P + Human albumin (Placebo) | CSL | Phase 2/3 | 64 |
| BE1116 + FFP | CSL | Phase 3 | 76 |
| CSL730 + Placebo | CSL | Phase 1 | 32 |
| vigabatrin | Lundbeck | Approved | 82 |
| Sabril | Lundbeck | Approved | 82 |